The international Journal ‘PAIN” is the official organ of the IASP, the Internationals Association for the study of Pain. Already 37 papers were published in PAIN giving attention to PEA.
In this key journal in the field of PAIN the first paper refering to PEA was published in 1998, and in this paper it was highlighted that cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors differential sensitivity to anandamide and palmitoylethanolamide. (Pain. 75(1):111-119, March 1998.)
Jaggar et al (Pain. 76(1-2):189-199, May 1998) in the same year showed that both anandamide (at a dose of 25 mg/kg) and palmitoylethanolamide (at doses of 10–30 mg/kg) were able to attenuate the viscero‐visceral hyper‐reflexia (VVH) induced by inflammation of the urinary bladder.
Sinde these 2 publications another 35 were published, up to 2015. PEA keeps researchers busy. However, more important is that it should now land in the hands of skilled clinicians, working in the field of pain. Because all this science is meant to help patients. It is a shame that MDs are blind for the efficacy of PEA, because it is a foodsupplement. A safe compound with an NNT of 1.5 should be used much more to help suffering patients!